[go: up one dir, main page]

WO2012174312A3 - Benzimidazole derivatives as antiviral agents - Google Patents

Benzimidazole derivatives as antiviral agents Download PDF

Info

Publication number
WO2012174312A3
WO2012174312A3 PCT/US2012/042558 US2012042558W WO2012174312A3 WO 2012174312 A3 WO2012174312 A3 WO 2012174312A3 US 2012042558 W US2012042558 W US 2012042558W WO 2012174312 A3 WO2012174312 A3 WO 2012174312A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiviral agents
benzimidazole derivatives
formulas
iii
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/042558
Other languages
French (fr)
Other versions
WO2012174312A2 (en
Inventor
Janos Botyanszki
Scott Howard Dickerson
Martin Robert Leivers
Xiaofei Li
Robert Blount Mcfadyen
Aniko Maria REDMAN
John Bradford SHOTWELL
Jianjun Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of WO2012174312A2 publication Critical patent/WO2012174312A2/en
Publication of WO2012174312A3 publication Critical patent/WO2012174312A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are compounds of Formulas I, II, III, IV, V, and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV). Also provided are synthetic intermediates, methods for preparing the compounds of any of Formulas I, II, III, IV and V or a pharmaceutically acceptable salt or solvate thereof, and compositions thereof and for their therapeutic uses.
PCT/US2012/042558 2011-06-15 2012-06-15 Benzimidazole derivatives as antiviral agents Ceased WO2012174312A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161497113P 2011-06-15 2011-06-15
US61/497,113 2011-06-15

Publications (2)

Publication Number Publication Date
WO2012174312A2 WO2012174312A2 (en) 2012-12-20
WO2012174312A3 true WO2012174312A3 (en) 2013-02-28

Family

ID=47357751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/042558 Ceased WO2012174312A2 (en) 2011-06-15 2012-06-15 Benzimidazole derivatives as antiviral agents

Country Status (1)

Country Link
WO (1) WO2012174312A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI574962B (en) 2012-11-14 2017-03-21 加拓科學公司 Heteroaromatic compounds as pi3 kinase modulators and methods of use
RU2672910C9 (en) 2013-02-21 2019-06-04 Калитор Сайенсез, ЛЛС Heteroaromatic compounds as phosphatidylinositol 3-kinase modulators
CN103435618B (en) * 2013-08-22 2016-03-23 中国药科大学 A kind of method of synthesizing fused heterocyclic compound
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CN105218413A (en) * 2015-08-12 2016-01-06 诚达药业股份有限公司 Prepare the method for aromatic sulphonic acid compounds
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
RU2739489C2 (en) * 2018-03-06 2020-12-24 Закрытое Акционерное Общество "Биокад" Novel heterocyclic compounds as cdk8/19 inhibitors
MX2020001531A (en) * 2017-08-07 2020-03-20 Biocad Joint Stock Co NEW HETOROCYCLIC COMPOUNDS AS INHIBITORS OF CDK8/19.
JP7258059B2 (en) * 2018-06-26 2023-04-14 昆薬集団股▲フン▼有限公司 Benzimidazole derivatives and their application as IDH1 inhibitors
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CN110551101B (en) * 2019-08-28 2020-11-24 沈阳药科大学 1. 6-disubstituted-benzo five-membered heterocyclic derivatives and their uses
US20250152599A1 (en) * 2020-03-13 2025-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd Anti-coronavirus effect and application of p14k inhibitor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166219A (en) * 1995-12-28 2000-12-26 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US20070093659A1 (en) * 2003-12-18 2007-04-26 Jean-Francois Bonfanti Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
US20090163489A1 (en) * 2007-12-19 2009-06-25 Shon Booker Inhibitors of PI3 kinase
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2010100144A1 (en) * 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
WO2010133318A1 (en) * 2009-05-20 2010-11-25 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166219A (en) * 1995-12-28 2000-12-26 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US20070093659A1 (en) * 2003-12-18 2007-04-26 Jean-Francois Bonfanti Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
US7687638B2 (en) * 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20090163489A1 (en) * 2007-12-19 2009-06-25 Shon Booker Inhibitors of PI3 kinase
WO2010100144A1 (en) * 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
WO2010133318A1 (en) * 2009-05-20 2010-11-25 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins

Also Published As

Publication number Publication date
WO2012174312A2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012174312A3 (en) Benzimidazole derivatives as antiviral agents
WO2011041713A3 (en) Piperazinyl antiviral agents
HRP20211224T1 (en) Pyrimidine derivatives for the treatment of viral infections
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
PH12015500749A1 (en) 2`chloro nucleoside analogs for hcv infection
MX372534B (en) POLYCYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE.
NZ628445A (en) Antiviral compounds with a heterotricycle moiety
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
MD20140135A2 (en) Macrocyclic inhibitors of Flaviviridae viruses
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
WO2012125926A3 (en) Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
EA201290053A1 (en) FLAVIVIRIDAE VIRUS INHIBITORS
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
UA108221C2 (en) THIOPHENE-2-CARBIC ACID DERIVATIVES AS FLAVIVIRIDAE VIRUS INHIBITORS
NZ603310A (en) Heterocyclic flaviviridae virus inhibitors
WO2012166716A3 (en) Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
MX2013006475A (en) Macrocyclic inhibitors of flaviviridae viruses.
UY31685A (en) ANTIVIRAL COMPOUNDS, COMPOSITIONS AND METHODS TO USE THEM
GEP20156263B (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for production and usage thereof
MX2012008211A (en) Inhibitors of flaviviridae viruses.
IN2012DN01855A (en)
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
JO3281B1 (en) Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections
EA201000051A1 (en) ANTI-VIRUS COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CO6300847A2 (en) ANTI-VIRAL COMPOUNDS COMPOSITIONS AND METHODS OF USE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12800521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM F1205 DATED 02-04-2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12800521

Country of ref document: EP

Kind code of ref document: A2